Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31 st Edition

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

(2020) Ivan Titov et al.   CLINICAL INFECTIOUS DISEASES

Clinical Utility of Lefamulin: If Not Now, When?

(2020) Nicholas J. Mercuro et al.   Current Infectious Disease Reports

Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020

(2020) Sancta St. Cyr et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

(2019) Joshua P. Metlay et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

(2019) Pratik Bhagunde et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

(2019) Marin H Kollef et al.   LANCET INFECTIOUS DISEASES

In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance United States 2015-2017

(2019) James A. Karlowsky et al.   Journal of Global Antimicrobial Resistance

Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence

(2018) Phoebe C. M. Williams et al.   Paediatrics and International Child Health

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

(2017) Matthew Sims et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase II Clinical Study of BC-3781, a Pleuromutilin Antibiotic, in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections

(2013) W. T. Prince et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY